Sucampo Pharmaceuticals, Inc. Announces Second Quarter 2014 Financial Results and Corporate Update Teleconference and Webcast on August 5
22 juil. 2014 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., July 22, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will host its second quarter 2014...
AMITIZA(R) (Lubiprostone) Receives NICE Recommendation
17 juin 2014 20h06 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., June 17, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that the United Kingdom's (U.K.) National...
Sucampo Issues Statement Regarding Anesthetic and Analgesic Drug Products Advisory Committee Meeting's Vote
12 juin 2014 14h41 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., June 12, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today issued the following statement regarding the...
Sucampo Announces Webcast of Its Presentation at 2014 Jefferies Global Healthcare Conference
29 mai 2014 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 29, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate...
Sucampo Announces Webcast of Its Presentation at the 2014 UBS Global Healthcare Conference
13 mai 2014 16h02 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 13, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, today announced that it will webcast its corporate...
Sucampo Pharmaceuticals, Inc., Reports First Quarter 2014 Financial and Operating Results
07 mai 2014 16h02 HE
|
Sucampo Pharmaceuticals Inc
Strong Financial Performance Driven by Year over Year Income and Revenue Growth
Company to host conference call today at 5:00 pm Eastern
BETHESDA, Md., May 7, 2014 (GLOBE NEWSWIRE) -- Sucampo...
Sucampo Announces New Data on AMITIZA and Opioid-Induced Constipation Published Online in Pain Medicine Journal
06 mai 2014 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 6, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), a global biopharmaceutical company, announced that its recent study, "A Randomized Study of...
Sucampo Announces Clinical Data on Lubiprostone to be Presented at Two Upcoming Scientific Conferences
01 mai 2014 06h45 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., May 1, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. ("Sucampo") (Nasdaq:SCMP), a global biopharmaceutical company, today announced that clinical data for lubiprostone will be...
Sucampo and Takeda Announce Update on Liquid Formulation Program for AMITIZA(R) (lubiprostone)
14 mars 2014 17h29 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., March 14, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharma Americas, LLC, a wholly owned subsidiary of Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP), and its development and...
Sucampo Receives Notice that Second Indication for AMITIZA for Opioid-Induced Constipation Is Not Approved by Medicines and Healthcare Products Regulatory Agency in U.K.
12 mars 2014 20h00 HE
|
Sucampo Pharmaceuticals Inc
BETHESDA, Md., March 12, 2014 (GLOBE NEWSWIRE) -- Sucampo Pharmaceuticals, Inc. (Sucampo) (Nasdaq:SCMP) today announced that Sucampo Pharma Europe, Ltd., its wholly owned subsidiary, has received a...